EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
JBT Marel Corporation
JBTM

JBTM JBT Marel Corporation

JBT Marel Corporation · NYSE
Market Closed
114.38
▲ ⁦+1.76%⁩ (+1.98)
Market Cap$5.9B
Beta0.94
52w Low52w High
110.19170.19
Last Week
⁦-1.74%⁩
Last Month
⁦-6.32%⁩
Last 3 Months
⁦-14.93%⁩
Last Year
⁦-21.76%⁩
EL7 Factor Analysis
How we score this
Overall55
Balanced — near the middle of the marketContrarianF 4/9Grey zoneBetter than 55% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
59
30.9x▼17.8xAround median
▸
Growth
90
44.9%▲7.1%Top tier
▸
Quality
54
3.8%▼4.5%Around median
▸
Safety
61
2.8x▼2.6xAround median
▸
Capital Return
34
0.35%▼2.12%Bottom tier
▸
Momentum
16
-17.4%▼2.9%Bottom tier
▸
Sentiment
75
6▲3Top tier
Fair Value
Current price$114
Analyst target · 2 analysts
$158
⁦+38%⁩
See it clearly undervalued
Range ⁦$150–$175⁩
vs
DCF (estimate)
$64
⁦-44%⁩
Sees it clearly overvalued
⁦8.5⁩% discount · ⁦1⁩% growth
Bottom lineThe two methods disagree — estimate range ⁦$64–$158⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 2 analysts setting price target
$160.00
⁦+39.9%⁩
Current Price $114.38·Median $157.50
Low
$150.00
High
$175.00
Current price
$114.38
Average target
$160.00
Street summary

A Relative Reduction in Consensus While Valuations Remain Positive

The consensus price target remained at 160, unchanged over one day, but declined from 163.33 seven days ago and 170 30 days ago—decreases of 2.04% and 5.88%, respectively. Meanwhile, the number of analysts covered increased from one to two, making the current comparison slightly broader, with a range between 150 and 175 and a median of 157.5, reflecting limited variation among the available estimates.

As of 2026-09-11
Revisions momentum · 30d
⁦-5.9%⁩
Average rating
★ 3.71
Buy
Analyst coverage
⁦7 (+1)⁩
New coverage
Buy conviction
86%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
22%
Analyst ratings over time7 analysts rating
1
5
1
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.67 → 3.71
Recent analyst moves
  • = Reiterate2026-09-08
    Barclays
    Overweight
  • = Reiterate2026-08-25
    KeyBanc
    Overweight
  • = Reiterate2026-05-21
    Oppenheimer
    Outperform· $175.00
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    30.91x
    5.69x45.54x
    Near median
  • Forward P/E
    12.85x
    4.57x36.58x
    Cheap
  • EV / EBITDA
    13.97x
    3.43x27.47x
    Near median
  • FCF Yield
    5.2%
    -32.7%11.5%
    Strong
  • Revenue Growth YoY
    44.9%
    -10.7%43.4%
    Exceptional
  • EPS Growth YoY
    261.6%
    -128.3%132.7%
    Exceptional
  • Gross Margin
    35.6%
    8.6%54.6%
    Above average
  • ROIC
    3.8%
    -25.3%19.6%
    Above average
  • Net Debt / EBITDA
    2.77x
    0.55x4.37x
    Near median
  • Dividend Yield
    0.3%
    0.1%4.8%
    Low
  • Payout Ratio
    11.3%
    6.6%80.8%
    Low
  • Altman Z-Score
    1.93
    -5.667.97
    Above average
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-08-04 data

Company Overview

JBT Marel Corporation provides integrated food and beverage processing and automation solutions, including technologies for primary and secondary protein processing, food forming, coating, frying, and heating, end-of-line solutions, and warehouse automation. The company generates revenue from equipment sales and aftermarket services and parts, and operates through the Protein Solutions and Prepared Food and Beverage Solutions segments; approximately 70% of its total revenue is also linked to protein markets, making spending by poultry and protein producers a key driver of its business.

In quarter 2 of fiscal year 2026, revenue reached $981 million, up 5% year over year, consisting of 3% organic growth and a 2% positive currency impact. Gross profit was $359 million, representing a gross margin of approximately 36.6%, while net income was $28 million and earnings per share were $0.54; adjusted earnings before interest, taxes, depreciation, and amortization were $168 million, with a margin of approximately 17.1%. Compared with quarter 1 of fiscal year 2026, revenue increased from $936 million and gross profit rose from $329 million, but net income declined from $45 million.

The Protein Solutions segment generated revenue of $467 million in quarter 2 of fiscal year 2026, representing approximately 47.6% of consolidated revenue, and grew 11% year over year, including 8% organically and 3% from currency. Prepared Food and Beverage Solutions mathematically accounted for approximately $514 million of revenue, but remained flat year over year despite a positive currency impact of approximately 2%, due to logistics constraints and production inefficiencies during the optimization of the plant network. On a trailing-twelve-month basis through the latest period, the company recorded revenue of $3.9 billion, gross profit of $1.4 billion, and net income of $166.7 million.

What's Driving the Stock

  • Orders increased 10% year over year in quarter 2 of fiscal year 2026, marking the third consecutive quarter in which orders exceeded $1 billion, while the record backlog covers more than 90% of equipment revenue for the second half of fiscal year 2026.
Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

  • Prepared Foods led with approximately 15% year-over-year order growth, while cross-selling initiatives generated $45 million in synergy orders during the first six months of fiscal year 2026 and $75 million over 18 months. Examples include a multi-line order combining forming, coating, frying, and heating technologies to produce fully cooked chicken.
  • The Protein Solutions segment grew 11% year over year to $467 million in quarter 2 of fiscal year 2026, supported by strong poultry investment and improved operating leverage; the order book also extends into fiscal year 2027, while Prepared Foods surpassed primary and secondary poultry processing in the pace of investment during the quarter.
  • Management maintained its fiscal year 2026 revenue guidance of between $3.99 billion and $4.07 billion, with consolidated growth of 6% at the midpoint and an expected 145-basis-point expansion in the adjusted earnings before interest, taxes, depreciation, and amortization margin. For quarter 3 of fiscal year 2026, it expects organic revenue growth of between 2% and 4%, a 1% negative currency impact, and an adjusted margin of between 17% and 17.5%.
  • Facility consolidation initiatives are targeting annual savings of $25 million to $30 million by fiscal year 2028, compared with an original estimate of between $10 million and $15 million, including $4 million to $5 million within the fiscal year 2026 outlook. Consolidating two warehouse automation facilities into one is expected to add approximately $9 million in annual savings, including about $3 million in the second half of fiscal year 2026.
  • Buying & Selling Case

    ▲ Buying Case4 pts

    • +The record order backlog, which covers more than 90% of equipment revenue for the second half of fiscal year 2026 and extends into fiscal year 2027, provides a high degree of revenue visibility relative to the nature of the industrial equipment business.
    • +Approximately 15% growth in Prepared Foods orders and $45 million in cross-selling orders during the first six months of fiscal year 2026 demonstrate that combining JBT and Marel technologies has begun generating actual synergy revenue, rather than merely expected cost savings.
    • +Protein Solutions revenue increased 11% year over year to $467 million, and its adjusted margin improved even after excluding the tariff refund, benefiting from poultry business volumes, synergy actions, and continuous improvement.
    • +The company generated $179 million in free cash flow from the beginning of fiscal year 2026 through the end of quarter 2, equivalent to 58% of adjusted earnings before interest, taxes, depreciation, and amortization, while leverage declined to just below 2.5 times, within the target range of between 2 times and 2.5 times.

    ▼ Selling Case6 pts

    • −Approximately 70% of JBT Marel revenue is linked to protein markets, and poultry is the largest category within Protein Solutions; therefore, a slowdown in the poultry investment cycle could have a material impact, despite current order strength. The beef market was also clearly the weakest because of limited cattle inventories, although beef represents less than 5% of the Protein Solutions portfolio.
    • −Prepared Food and Beverage Solutions performed below management's expectations in quarter 2 of fiscal year 2026, as approximately $20 million of revenue was delayed because of logistics availability and production inefficiencies during the transfer of operations. Management estimated the impact of this delay on adjusted earnings before interest, taxes, depreciation, and amortization at approximately $5 million to $6 million, making achievement of the outlook dependent on revenue recovery and improved execution during the second half.
    • −Higher logistics, metals, and input costs are pressuring margins, and the company did not fully recover logistics inflation through pricing in quarter 2 of fiscal year 2026. The company spends more than $100 million annually on logistics, with approximately 60% to 65% related to inbound freight and intercompany shipping, both of which are more difficult to pass on to customers.
    • −The plant network optimization plan involves extended execution risks, after operational transfers already contributed to production inefficiencies and delayed revenue recognition. The plan includes reducing global space by approximately 15%, or 1.3 million square feet, while major facility consolidation efforts continue through the end of fiscal year 2027; therefore, the targeted savings of $25 million to $30 million by fiscal year 2028 remain dependent on an orderly transition without additional disruptions.
    • −The company recorded a non-cash impairment charge to write off intangible assets associated with the 2021 Prevenio transaction, after customer demand shifted from its value-added antimicrobial poultry solutions toward a more commodity-like approach. This indicates specific economic weakness in this offering despite strong growth across the rest of Protein Solutions.
    • −The valuation carries risk related to analysts' targets being near the upper end of the 52-week range; the average target of $163.33 is only approximately 4% below the range high of $170.19, while the target range extends from $150 to $175. The context does not provide a valid earnings multiple that can be used to test whether expectations for margin expansion through fiscal year 2028 are already reflected in the valuation.

    Valuation

    The analyst consensus is “Buy,” with an average price target of $163.33 and a target range of between $150 and $175. The average is near the upper end of the 52-week range of $113.23 to $170.19, while the highest target exceeds the top of that range by only approximately 2.8%; this optimism is counterbalanced by a low target of $150 and the execution risks of plant optimization and input pressures. No reliable earnings multiple is available in the data, so the stock's valuation rests primarily on the company's ability to deliver the targeted margin expansion and reach an adjusted margin of 20% in fiscal year 2028.

    BuyAnalyst target: $163.33(+42.8%)

    Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.

    FAQ

    What were JBT Marel's key results in quarter 2 of fiscal year 2026?

    Revenue reached $981 million in quarter 2 of fiscal year 2026, up 5% year over year, including 3% organic growth and 2% from currency. The company recorded gross profit of $359 million, a gross margin of approximately 36.6%, net income of $28 million, and earnings per share of $0.54. Adjusted earnings before interest, taxes, depreciation, and amortization were also $168 million, representing a margin of approximately 17.1%.

    What is JBT Marel's outlook for fiscal year 2026?

    Management reaffirmed its fiscal year 2026 revenue outlook of between $3.99 billion and $4.07 billion, equivalent to consolidated growth of 6% at the midpoint. It also expects a 145-basis-point expansion in the adjusted earnings before interest, taxes, depreciation, and amortization margin at the midpoint. For quarter 3 of fiscal year 2026, it expects organic growth of between 2% and 4% and an adjusted margin of between 17% and 17.5%, with a 1% negative currency impact.

    Why are poultry and Prepared Foods orders important for JBTM stock?

    Exposure to protein markets represents approximately 70% of the company's revenue, and poultry remains the largest category in Protein Solutions. Prepared Foods orders increased approximately 15% year over year in quarter 2 of fiscal year 2026, while the company recorded $45 million in cross-selling orders during the first six months of the year. The order backlog extends into fiscal year 2027, but the continuation of this strength depends on spending by poultry and protein producers remaining at elevated levels.

    How does JBT Marel plan to improve profit margins?

    The company is consolidating its manufacturing and distribution network and has announced a reduction of approximately 1.3 million square feet, equivalent to about 15% of its global footprint. It expects these initiatives to generate annual savings of between $25 million and $30 million by fiscal year 2028, including $4 million to $5 million incorporated into the fiscal year 2026 outlook. It also targets approximately $9 million in annual savings from the warehouse automation restructuring, while the long-term goal remains reaching an adjusted earnings margin of 20% in fiscal year 2028.

    What are the most important operational risks facing JBT Marel?

    Logistics constraints and production inefficiencies delayed approximately $20 million of Prepared Food and Beverage Solutions revenue in quarter 2 of fiscal year 2026, with an impact of $5 million to $6 million on adjusted earnings before interest, taxes, depreciation, and amortization. The company spends more than $100 million annually on logistics and did not fully recover the inflation in these costs through pricing during the quarter. Facility consolidation efforts also continue through the end of fiscal year 2027, maintaining the possibility of additional disruptions during the transition.

    How does JBT Marel use cash flow and capital?

    The company generated $179 million in free cash flow from the beginning of fiscal year 2026 through the end of quarter 2, representing a conversion rate equal to 58% of adjusted earnings before interest, taxes, depreciation, and amortization. Leverage declined to just below 2.5 times, entering the target range of between 2 times and 2.5 times. During the quarter, it repurchased $26 million of shares under an announced $200 million authorization and also declared quarterly cash dividends, while continuing to balance debt reduction against share repurchases.